No profile data available.
Windtree Therapeutics, Inc. (WINT) is a healthcare company in the cardiac treatment pharmaceuticals industry, based in Warrington, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$5.49 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $33,708 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.
Windtree Therapeutics reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$33,708 as of October 8, 2026.
Listed companies of a similar size in the same industry (cardiac treatment pharmaceuticals) include Tenaya Therapeutics, Inc. (TNYA), Cardiol Therapeutics Inc. (CRDL), Milestone Pharmaceuticals Inc. (MIST).